Statement Of Changes In Equity [Abstract]

Hyloris Pharmaceuticals SA - Filing #5880974

Concept	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	86,471,000 EUR	121,513,000 EUR	140,000 EUR	—	—	—	476,000 EUR	945,000 EUR	32,143,000 EUR	4,460,000 EUR	—	39,069,000 EUR	80,761,000 EUR	476,000 EUR	—	121,513,000 EUR	140,000 EUR	—	2,162,000 EUR	4,460,000 EUR	53,909,000 EUR	476,000 EUR	121,513,000 EUR	1,622,000 EUR	65,381,000 EUR	140,000 EUR	4,460,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	—	—	—	—	6,342,000 EUR	—	—	—	—	—	15,380,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other comprehensive income	—	—	—	—	- EUR	—	—	—	—	—	- EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Comprehensive income	—	—	—	6,342,000 EUR	6,342,000 EUR	—	—	—	—	—	15,380,000 EUR	—	—	—	15,380,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	—	—	—	—	584,000 EUR	584,000 EUR	—	—	—	—	540,000 EUR	—	—	—	—	—	—	540,000 EUR	—	—	—	—	—	—	—	—	—